Antivirals. Paxlovid does not come off in the pharmacy: in just one month 2000 treatments

It is difficult to quit using Pfizer’s antivirals, which if used within five days of symptoms appearing can prevent an 80% risk of hospitalization. Although it can be prescribed by general practitioners and also distributed in local pharmacies, in just over a month only 2,210 people were able to pick it up from the pharmacy. A real failure. By mid-2022, only 20,392 people were able to benefit from this drug even though Italy has selected 600,000 treatments for the current year.

June 21 –

It is difficult to quit using Pfizer’s antivirals, which if used within five days of symptoms appearing can prevent an 80% risk of hospitalization. Although it can be prescribed by general practitioners and also distributed in local pharmacies, in just over a month only 2,210 people were able to pick it up from the pharmacy. A real failure. By mid-2022, only 20,392 people were able to benefit from this drug even though Italy has selected 600,000 treatments for the current year.

The possibility of its prescribing by general practitioners was not sufficient before, and its distribution in local pharmacies does not seem sufficient now. In Italy, a prescription for Paxlovid, Pfizer’s antiviral against Covid, is struggling to quit, which, if taken within five days of onset of symptoms, prevents the risk of hospitalization by 80%.

In just over a month, only 2,210 people were able to pick it up from the pharmacy. For now, even this solution appears to be a real failure. By mid-2022, only 20,392 people were able to benefit from this drug even though Italy has selected 600,000 treatments for the current year. An inexplicable number given that every month in Italy thousands of people with the Covid virus continue to die. To what then can we attribute this rare use of the drug?

One of the main problems can be with mandatory restrictions. Personal data, advanced age, is not sufficient to consider them as people at risk of developing severe forms of Covid and therefore suitable for receiving this treatment. In fact, Baxolvid is still prescribed for the treatment of adult patients who do not require supplemental oxygen therapy and who are “at high risk of severe COVID-19 infection, such as patients with neoplastic disease, cardiovascular disease, decompensated diabetes, chronic lung disease, and severe obesity.” This decision becomes enforceable by publishing Aifa’s decision in the Official Gazette on April 20.

Another element to consider, former CEO Emma and advisor to General Figliolo, Guido Rassi, told us may have to do with the need for greater training on the part of family physicians, and who first should donate help. Increased use of these drugs for high-risk patients.

June 21 2022
© All Rights Reserved

Other articles in Science and Drugs